PIONEERING
PRECISION MEDICINE FOR BRAIN DISORDERS

Read more about Stalicla

Pipeline

Table of stalicla pipeline.
ASD = Autism Spectrum Disorder NAM = Negative Allosteric Modulator

Latest News

Read more

STALICLA - Une révolution dans la médecine de précision pour l’autisme

Read more

Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor

Read more

STALICLA publishes on identification of first autism subgroup and matching treatment

Read more

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant)

See full text job-arrow

Stalicla’s series B adds $17.4M for trials in substance abuse disorders, ASD

Read more

STALICLA secures $17.4 Million in Series B Round

Read more

Network medicine and molecular endotypes to further dementia research

Read more

STALICLA on Swiss RTS TV

Read more

STALICLA at Synchrony 2022

Read more

STALICLA and Firefly Neuroscience partner to develop Electroencephalogram (EEG) as Biomarker for Subgroups of Patients with ASD

Read more

STALICLA signs with National Institute on Drug Abuse (NIDA) for Phase 3 development of mavoglurant in cocaine use disorder

See full text job-arrow

La start-up genevoise Stalicla qui veut traiter l’autisme change de dimension

See full text job-arrow

Stalicla Inks Mavoglurant Deal With Novartis

Read more

Novartis offloads neurodevelopmental disorder asset to small Swiss biotech

See full text job-arrow

Stalicla pledges $270M to take forward Novartis' failed former fragile X candidate

See full text job-arrow

STALICLA signs agreement with Novartis on neurodevelopmental disorders

Read more

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

See full text job-arrow

Stalicla to acquire rights to Novartis cocaine addiction candidate

See full text job-arrow

Stalicla Seals Deal To Advance Novartis Drug For Cocaine Misuse

Read more

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

Read more

STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study

See full text job-arrow

STALICLA strengthens pipeline to advance precision medicine for Autism Spectrum Disorders

Read more

Innovative SME recognition

Read more

Women in Data Science congress sponsorship

See full text job-arrow

STALICLA to in-license SFX-01 from Evgen for neurodevelopmental disorder indications

Read more

STALICLA will be leading computational drug repositioning in EU-funded project REPO4EU

Read more

STALICLA completes successful phase 1b trials for the first precision medicine in autism spectrum disorder

Read more

STALICLA at the first NDD Summit in 2021

Read more

Publication of our review on the Heterogeneity in Fragile X Syndrome

Read more

Partnership between STALICLA and UB

Read more

STALICLA Appoints B. Gomez-Mancilla, MD, PhD

Read more

Virtual fireside talk with Craig Erickson

Read more

Working at STALICLA: Interview with Laura Perez-Cano

Read more

3 clinical trials led by STALICLA on portal of the World Health Organization (WHO) and ClinicalTrials.gov

Read more

Global entrepreneurship week event - featuring STALICLA's founder, Lynn Durham

Read more

STALICLA becomes a clinical stage company, with the approval of its STP1 investigational new drug (IND) application by the FDA

See full text job-arrow

Premier essai clinique de médecine personnalisée

See full text job-arrow

Swiss Biotech STALICLA Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A

See full text job-arrow

Successful closure of the 2018 tranche of its series A round for a total amount of CHF 10M

Read more

Bilan – Janvier 2020 : Innovation - featuring STALICLA CEO

Read more

AGEFI - 27 Novembre 2019 : Stalicla accélère sa croissance vers le traitement de l’autisme

See full text job-arrow

TRIBUNE DE GENEVE - 20 Novembre 2019 : Nouvelle étape dans la lutte contre l’autisme de Stalicla

See full text job-arrow

Premier traitement testé l’an prochain

Read more

AGEFI - 12 Novembre 2019 : Stalicla: vers un premier essai clinique de médecine personnalisée

See full text job-arrow

STALICLA appoints Stéphane Baudouin as Chief of Science

See full text job-arrow

Lynn Durham speaks to Royal Netherlands Academy of Arts and Sciences Colloquium on Neurodevelopmental Disorders

See full text job-arrow

STALICLA completes FDA pre-IND Meeting on STP1 for Subgroup of Patients With Autism Spectrum Disorder

See full text job-arrow

Bilan a dévoilé le 1er mars dernier sa selection de 50 start-up suisses pour investir ou s’inspirer.

Read more

Entrepreneur stories: Lynn-Allison Durham (The bigdata to cure autism)

See full text job-arrow

Stalicla, uma startup genebrina, recorre a algoritmos para definir perfil biológico de cada grupo de autistas e, assim, identificar fármacos mais eficazes.

Read more

STALICLA’s CEO & founder’s interview on CNNmoney.ch from November 21st is available to stream online

See full text job-arrow

Genfer Startup will Big Pharma den Meister zeigen

Read more

STALICLA développe un traitement pharmacologique inédit des troubles du spectre de l’autisme

Read more

Private Company Spotlight

Read more

Une start-up genevoise bouleverse la manière de traiter l’autisme

Read more

Partnership with the Greenwood Genetic Center (GGC)

See full text job-arrow

STALICLA selected among the 2018 top 50 start-ups in Switzerland